MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.50 (1,081.82% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetActions
12/15/2015JMP SecuritiesBoost Price TargetMarket Outperform$9.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2015OppenheimerReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2015OppenheimerInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Stifel NicolausLower Price TargetBuy$20.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseDowngradeOutperform -> Neutral$20.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2014Credit SuisseReiterated RatingOutperform$21.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/8/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha